BACKGROUND: We assessed the utility of the dual PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235) as single agent therapy and in combination with conventional chemotherapy for thyroid cancer. METHODOLOGY/PRINCIPAL FINDINGS: Eight cell lines from four types of thyroid cancer (papillary. follicular. anaplastic. https://www.ealisboa.com/great-deal-Pentair-Union-Collar-2-U11-200PS-super-offer/